Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Nürnberg – page 3

141 clinical trials in Nürnberg, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Nürnberg at a glance
141
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

141 trials in Nürnberg

Open in trial search

Hormone-refractory prostate cancer

Recruiting

A Study of JNJ-78278343 Compared to Placebo for Patients with Advanced Prostate Cancer That No Longer Responds to Hormone Treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:JNJ-78278343
  • Sponsor:Janssen Cilag International

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Congenital cystic kidney disease

Recruiting

Testing dapagliflozin to slow kidney function decline in patients with autosomal dominant polycystic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Dapagliflozin
  • Sponsor:University Of Cologne

Ischaemic stroke

Recruiting

A study testing tenecteplase given directly into the artery after blood clot removal in patients with acute ischemic stroke in the front part of the brain

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Small cell lung cancer recurrent

Recruiting

Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:GSK5764227
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas+1

Recruiting

Study of drug combination therapy after surgery in patients with resectable pancreatic ductal adenocarcinoma using lab-grown mini-tumors to guide treatment selection

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Universitaetsklinikum Ulm AöR

Hormone-refractory prostate cancer+1

Recruiting

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma refractory

Recruiting

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Pancreatectomy

Recruiting

Study on Hydrocortisone for Patients Undergoing Pancreatic Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Acute myeloid leukaemia+1

Recruiting

Study Comparing Treosulfan and Melphalan with Fludarabine for Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Undergoing Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fludarabine
  • Sponsor:Technische Universitat Dresden

Colon cancer stage III+1

Recruiting

Study on Pre-Operative Chemotherapy with Disodium Folinate, Oxaliplatin, and Fluorouracil for Patients with Advanced Resectable Colon Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Neonatal respiratory distress syndrome

Recruiting

Study comparing prophylactic versus selective surfactant (poractant alfa, phospholipid fraction) administration in preterm infants with respiratory distress syndrome aged 25-30 weeks

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Poractant Alfa
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Nürnberg

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focused on treating multiple myeloma, breast cancer, and melanoma. Studies evaluate novel therapies including CAR T-cell treatments and targeted immunotherapies.

  • Multiple Myeloma Treatments
  • Breast Cancer Therapies
  • Melanoma Management

Advanced research includes investigation of new combination therapies and maintenance treatments post-transplantation.

02 Cardiovascular Studies

Innovative research targeting atherosclerotic cardiovascular disease and related conditions. Trials evaluate new medications for managing cholesterol and reducing major cardiovascular events.

  • Cholesterol Management
  • Cardiovascular Risk Reduction
  • Pulmonary Embolism Treatment

Focus on developing treatments to improve patient outcomes in cardiovascular conditions.

03 Immunology and Inflammation

Clinical studies examining treatments for inflammatory myopathies and psoriatic arthritis. Research focuses on innovative therapies and disease management approaches.

  • Inflammatory Disease Treatment
  • Autoimmune Conditions
  • Immunotherapy Applications

Emphasis on developing targeted treatments for severe inflammatory conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.